Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 45:1157-1164, doi:10.1016/j.jacc.2005.01.034
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (101)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, T. A.
Right arrow Articles by Pharand, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, T. A.
Right arrow Articles by Pharand, C.

Resistance to clopidogrel: A review of the evidence

Thuy Anh Nguyen, MSc, Pharm*, Jean G. Diodati, MD{dagger},{ddagger},|| and Chantal Pharand, PharmD*,{ddagger},§,*

* Pharmacy Department, Hôpital du Sacré-Coeur de Montréal, Montreal, Canada
{dagger} Service of Cardiology, Hôpital du Sacré-Coeur de Montréal, Montreal, Canada
{ddagger} Research Centre, Hôpital du Sacré-Coeur de Montréal, Montreal, Canada
§ Faculty of Pharmacy, Université de Montréal, Montreal, Canada.
|| Faculty of Medicine, Université de Montréal, Montreal, Canada.



View larger version (29K):

[in a new window]
 
Figure 1 Mechanism of action of clopidogrel. Clopidogrel competitively and irreversibly inhibits the adenosine diphosphate (ADP) P2Y12 receptor; ADP binds to the P2Y1 receptor to induce change in platelet shape and a weak and transient platelet aggregation. The binding of ADP to its Gi-coupled P2Y12 receptor liberates the Gi protein subunits {alpha}Gi and ß{gamma}. The subunit {alpha}Gi leads to the inhibition of adenylyl cyclase (AC), which, in turn, lowers the cyclic adenosine monophosphate (cAMP) level. This inhibits the cAMP-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) (VASP-P), which is known to be closely related to the inhibition of glyprotein IIb/IIIa receptor activation. The subunit ß{gamma} activates the phosphatidylinositol 3-kinase (PI3K), which potentiates dense- and {alpha}-granule secretion. Multiple arrows within a given pathway indicate that intermediate steps may be involved. Dotted arrows indicate inhibition, whereas solid arrows represent activation. CYP450 = cytochrome P450; PGE1 = prostaglandin E1; PKA = protein kinase activation; PLC = phospholipase C.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement